©The Author(s) 2025.
World J Diabetes. Dec 15, 2025; 16(12): 112694
Published online Dec 15, 2025. doi: 10.4239/wjd.v16.i12.112694
Published online Dec 15, 2025. doi: 10.4239/wjd.v16.i12.112694
Table 2 Procedural outcomes of glucagon-like peptide-1 receptor agonist users and dipeptidyl peptidase 4 inhibitor users before and after matching, n (%)
| Characteristic | Before matching (n = 733) | After matching (n = 493) | ||||||
| Total (n = 733) | GLP-1RA (n = 208) | DPP4i (n = 525) | P value | Total (n = 493) | GLP-1RA (n = 198) | DPP4i (n = 295) | P value | |
| Inadequate gastric mucosal visibility | 27 (3.7) | 19 (9.1) | 8 (1.5) | < 0.0001 | 21 (4.3) | 17 (8.6) | 4 (1.4) | 0.0007 |
| Aborted EGD | 21 (2.9) | 16 (7.7) | 5 (1.0) | < 0.0001 | 17 (3.4) | 15 (7.6) | 2 (0.7) | 0.0011 |
| Repeat EGD | 21 (2.9) | 16 (7.7) | 5 (1.0) | < 0.0001 | 17 (3.4) | 15 (7.6) | 2 (0.7) | 0.0011 |
| Pulmonary aspiration | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA |
- Citation: Oh YE, Kim TS, Chi SA, Park HJ, Min YW, Lee H, Lee JH, Rhee PL, Kim JJ, Min BH. Effect of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility during upper endoscopy in Asian patients with diabetes. World J Diabetes 2025; 16(12): 112694
- URL: https://www.wjgnet.com/1948-9358/full/v16/i12/112694.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i12.112694